NEWNAN, Ga., July 17, 2026 /PRNewswire/ — Poriferous, LLC, a leading global manufacturer of SuᐧPor® craniomaxillofacial and patient-specific implants, has been awarded its patent for its innovative DuraBloc™ technology from the U.S. Patent and Trademark Office (USPTO), U.S. Patent No. 12,653,677, issued on June 16, 2026.
BOSTON, July 16, 2026 /PRNewswire/ — HoneyNaps, an AI-based sleep medicine company, today announced that SOMNUM V3.0, its AI diagnosis software for polysomnography (PSG) analysis, has received U.S. Food and Drug Administration (FDA) clearance under clearance number K253390.
The LightningWire system is designed to support transseptal access in procedures such as atrial fibrillation ablation, left atrial appendage closure and transcatheter mitral interventions.
LEXINGTON, S.C., July 15, 2026 /PRNewswire/ — ElectroWire Medical announced today that the U.S. Food and Drug Administration has granted 510(k) clearance for its LightningWireTM Transseptal Puncture System, which is indicated to create an atrial septal defect in the heart, whereby various cardiovascular catheters are introduced.
TORONTO, July 15, 2026 /PRNewswire/ — SpinaFX Medical Inc. (“SpinaFX”), a Toronto‑based medical device company specializing in image‑guided, minimally invasive spine care, today announced it has received Medical Device Regulation (MDR) CE Mark certification for its Triojection® System (MDR 843778).
Automated software helps respiratory therapists identify ineffective efforts, the most frequent type of patient-ventilator asynchrony in mechanically ventilated patients
B. Braun Medical Inc. announced the FDA approval of Sugammadex Injection, 200 mg/2 mL (100 mg/mL), AP-rated generic BRIDION®1* (Sugammadex Injection) in the U.S. market.
Newronika announced today that it secured CE mark for its latest adaptive deep brain stimulation (aDBS) system.
SUNNYVALE, Calif., July 13, 2026 /PRNewswire/ — Embolx, Inc., a leader in advanced microcatheter technology for targeted embolization procedures, today announced that the Centers for Medicare & Medicaid Services (CMS) has established a new HCPCS Level II code, G0577, covering Sniper® procedures performed in the physician office, or office-based lab (OBL), setting. The new code took effect July 1, 2026.
STOCKHOLM, July 13, 2026 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik®) as a starting dose for the treatment of early Alzheimer’s disease. The US launch is planned for late August 2026.